Recursion, Exscientia, and AI drug discovery’s moment of truth Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger.

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Read about Recursion Pharmaceuticals Inc Class A (RXRX:XNAS) stock and today's latest news and financial updates.

Review which funds and institutions currently hold Recursion Pharmaceuticals Inc Class A (RXRX:XNAS) stock for ownership information.

See Recursion Pharmaceuticals, Inc. (RXRX) Environment, Social and Governance Ratings to help you in your stock buying decisions.

Stay up-to-date on Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) news with the latest updates, breaking headlines, news articles, and more from around the web at Nasdaq.com.